← Leaderboards
Susan K. Schultz
University Of Iowa
$2,081,445
Attributed
$2,155,812
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $223.2K · FY2006–15$250K$187.5K$125K$62.5K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$2,155,812 · 6
By mechanism
R01$1,072,493 · 1
R21$551,250 · 1
K08$376,703 · 1
R03$148,735 · 1
M01$6,631 · 2
Top collaborators
- Laura Lynn Boles Ponto2 shared
Most similar at University Of Iowa
Same institution · by research overlap
- Donald D Heistad$11,093,459
- Steven R Lentz$22,602,998
- Ryan T Lalumiere$10,632,326
- Michael E.c. Robbins$8,053,669
- Frederick E Domann$2,914,825
Others in their field
Top investigators on “Memory”
- Julianne L Imperato-McGinley · Weill Medical College Of Cornell Univ$159,370,162
- Richard Farnsworth · Battelle Memorial Institute$133,681,131
- Paula M Mabee · South Dakota Health Technologies Innovations Inc$133,681,131
- Christopher McKay · Battelle Memorial Institute$133,681,131
- Ronald T Mitsuyasu · University Of California Los Angeles$99,239,507
- Olaf Schneewind · University Of California Los Angeles$87,583,896
Research focus
MemoryAlzheimer&AposParticipantS DiseaseTreatment EffectRelative (Related Person)SamplingImpaired CognitionBasePublic Health Medicine (Field)Brain VolumeOutcomes ResearchLongitudinal Human StudyCognitiveChronicHuman Old Age (65+)Human SubjectResourcesBiobehaviorAge EffectBreast Cancer TreatmentAcuteAgedBasal Ganglia
Grant awards (15)
Utility of Early Phase PIB as a Surrogate for Cerebral Blood Flow Measures$73,235
R03 · FY2015 · AG
Utility of Early Phase PIB as a Surrogate for Cerebral Blood Flow Measures$75,500
R03 · FY2014 · AG
Elderly Cancer Survivors: Cognitive Outcomes and Markers of Neurodegeneration$216,497
R01 · FY2011 · CA · contact PI
Elderly Cancer Survivors: Cognitive Outcomes and Markers of Neurodegeneration$223,193
R01 · FY2010 · CA · contact PI
Elderly Cancer Survivors: Cognitive Outcomes and Markers of Neurodegeneration$223,193
R01 · FY2009 · CA · contact PI
Elderly Cancer Survivors: Cognitive Outcomes and Markers of Neurodegeneration$204,940
R01 · FY2008 · CA · contact PI
Elderly Cancer Survivors: Cognitive Outcomes and Markers of Neurodegeneration$204,670
R01 · FY2007 · CA · contact PI
VALPROATE TO ATTENUATE THE PROGRESSION OF ALZHEIMER'S DISEASE (AD)$5,969
M01 · FY2007 · RR · contact PI
VALPROATE TO ATTENUATE THE PROGRESSION OF ALZHEIMER'S DISEASE (AD)$662
M01 · FY2006 · RR · contact PI
Cognitive Enhancers Explored with PET Imaging$183,750
R21 · FY2003 · MH
Cognitive Enhancers Explored with PET Imaging$183,750
R21 · FY2002 · MH
NEUROLEPTICS AND AGING--PREVENTING TARDIVE DYSKINESIA$129,192
K08 · FY2002 · MH
Cognitive Enhancers Explored with PET Imaging$183,750
R21 · FY2001 · MH
NEUROLEPTICS AND AGING--PREVENTING TARDIVE DYSKINESIA$125,532
K08 · FY2001 · MH
NEUROLEPTICS AND AGING--PREVENTING TARDIVE DYSKINESIA$121,979
K08 · FY2000 · MH